作者: Ana Giménez-Capitán , Niki Karachaliou , Miquel Tarón , Jordi Bertran-Alamillo , Rafael Rosell
DOI: 10.3978/J.ISSN.2218-6751.2013.02.06
关键词: Cancer 、 Circulating tumor cell 、 Antigen 、 Tumor progression 、 Malignancy 、 Medicine 、 Pathology 、 Antibody 、 Metastasis 、 Cancer research 、 Lung cancer
摘要: Circulating tumor cells (CTCs) can be detected in the blood of many cancer patients and play a key role metastasis. In addition, after development technologies with necessary sensitivity reproducibility, diagnostic potential these is being actively explored. Recently, U.S. Food Drug Administration has approved CellSearch ® System, based on magnetic beads coated epithelial cell-adhesion molecule (EpCAM) antibody. Despite its usefulness, this system miss CTCs that lose antigens due to epithelial-mesenchymal transition and, case advanced NSCLC, positivity demonstrated only 30-50% patients. an effort overcome drawbacks, new methods are developed. study, we have evaluated CK-coated as isolate from lung clinical setting, if they useful source material for genetic testing. We were able identify 17 30 included study (57%), range 1 7 cells. two them, found EMT pattern. CTC seemed correlate history malignancy. could more than 80% stage III-IV at presentation or samples taken immediately surgery. The percentage dropped 13% responding chemotherapy TKIs, raising again 57% progression. Finally, tested isolated 8 EGFR k-ras mutations, but gene amplification was successful 3 4 CTCs.<